The experience with the clinical application of liralgutide (victosa), the first analog of human glucagon-like peptide-1 in the patients with type 2 diabetes mellitus - expanding the range of possibilities
https://doi.org/10.14341/probl201258351-55
Abstract
References
1. IDF diabetes atlas, 5th edition, 2011.
2. Шестакова М.В. Cахарный диабет в пожилом возрасте: особенности клиники, диагностики и лечения. Consilium Medicum 2002; Том 04, № 10. http://old.consilium-medicum.com/media/consilium/02_10/544.shtml
3. Obesity and Overweight for Professionals: Data and Statistics: U.S. Obesity Trends. Centers for Disease Control and Prevention. 2011-07-21. http://www.cdc.gov/obesity/data/trends.html. Retrieved 2012-10-25
4. James P.T., Rigby N., Leach R. "The obesity epidemic, metabolic syndrome and future prevention strategies". Eur J Cardiovasc Prev Rehabil 2004; 11 (1): 3-8.
5. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (5-й выпуск). Сахарный диабет 2011; №3 (Приложение).
6. Nauck M.A., Meier J.J. Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes. Regul Pept 2005; 124 (suppl): 135-148.
7. Toft-Nielsen M.B., Madsbad S., Holst J.J. Determinants of the effectiveness of glucagonlike peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3853-3860.
8. Farilla L., Bulotta A., Hirshberg B., Calzi S.L., Khoury N., Noushmehr H., Bertolotto C., Di Mario U., Harlan D.M., Perfetti R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144(12):5149-5158.
9. Carnea S. The role of incretin therapy at different stages of diabetes. Rev Diabet Stud 2011; 8:323-338.
10. Flint A., Raben A., Ersbøll A.K., Holst J.J., Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes 2001; 25 (6): 781-792.
11. Hayes M.R., Leichner T.M., Zhao S., Lee G.S., Chowansky A., Zimmer D., De Jonghe B.C., Kanoski S.E., Grill H.J., Bence K.K. Intracellular signals mediating the food intake-suppressive effects of hindbrain glucagon-like peptide-1 receptor activation. Cell Metab 2011; 13(3):320-330.
12. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide-1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54 (1):146-151.
13. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide-1 receptor are mediated through both glucagon-like peptide-1 receptor-dependent and -independent pathways. Circulation 2008; 117: 2340-2350.
14. Gutzwiller J.P., Tschopp S., Bock A., Zehnder C.E., Huber A.R., Kreyenbuehl M., Gutmann H., Drewe J., Henzen C., Goeke B., Beglinger C. Glucagon-like Peptide-1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89(6):3055-3061.
15. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., Johansen N.L., Madsen K., Pedersen F.Z., Thøgersen H., Wilken M., Agersø H. Potent derivatives of glucagon-like peptide-1with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43(9):1664-1669.
16. Elbrønd B., Jakobsen G., Larsen S., Agersø H., Jensen L.B., Rolan P., Sturis J., Hatorp V., Zdravkovic M. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25 (8):1398-1404.
Review
For citations:
Ostroukhova E.N., Khmel'nitskiĭ O.K., Krasil'nikova E.I., Davidenko K.S. The experience with the clinical application of liralgutide (victosa), the first analog of human glucagon-like peptide-1 in the patients with type 2 diabetes mellitus - expanding the range of possibilities. Problems of Endocrinology. 2012;58(3):51-55. https://doi.org/10.14341/probl201258351-55
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
